Homology Medicines Added to the Russell 3000® and Russell 2000® Indexes

- Company Will Also Ring the Nasdaq Stock Market Opening Bell Today -

BEDFORD, Mass., June 25, 2018 – Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has been added to the Russell 3000® Index and Russell 2000® Index effective after the market opens today. Homology’s membership in the Russell US Indexes is determined primarily by objective, market-capitalization rankings and style attributes.

Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell US Indexes.

In other news today, Homology announced that it will ring the Nasdaq stock market Opening Bell this morning, and a live stream of the event will be available at https://new.livestream.com/nasdaq/live.

About Homology Medicines, Inc.

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visit www.homologymedicines.com.

Investor Contact:
Theresa McNeely
SVP, Corporate Communications &
Patient Advocacy
tmcneely@homologymedicines.com
781-301-7277, ext. 156

Media Contact:
Cara Mayfield
Director, Corporate Communications
cmayfield@homologymedicines.com
781-301-7277, ext. 141

< BACK